In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Rockwell Medical, Inc.. Trade Record

NASDAQ:RMTI Rockwell Medical, Inc. stock gains 46.61% Exit Mar 14, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart RMTI Feb 6, 2019, priceSeries
About Rockwell Medical, Inc.

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. The company's lead drug is Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment via dialysate. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company's targets customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.

Trade Information
Trade Type
LONG
ReliabilityScore™
86.24
Entry Date
Feb 6, 2019
Entry Price
3.27
Sell Date
Mar 14, 2019
Sell Price
4.79
Net Gain
46.61%
Hold Time
25 Trading Days